These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7055847)

  • 1. Surface activity and human blood platelet aggregation-inhibitory potency.
    Quintana RP; Lasslo A; Queen GS
    Chem Biol Interact; 1982 Jan; 38(2):135-44. PubMed ID: 7055847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interrelationships between the chemical structure of synthetic entities, their platelet aggregation inhibitory potency and their cellular toxicity, based on in vitro experiments.
    Lasslo A; Dillingham EO; McCastlain JC; Carter-Burks G; Quintana RP; Johnson RW; Naylor JL
    Med Prog Technol; 1986; 11(3):109-21. PubMed ID: 3796501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between the chemical constitution of aggregation inhibitors and human blood platelet response profile.
    Lasslo A; Quintana RP; Johnson RW; Naylor JL; Dugdale M
    Biochim Biophys Acta; 1984 Apr; 772(1):84-92. PubMed ID: 6424710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between chemical structure and inhibition of epinephrine-induced human blood platelet aggregation.
    Petrusewicz J; Lasslo A; Carter-Burks G; Gollamudi R; Dillingham EO; Bond SE
    Biochim Biophys Acta; 1989 Aug; 983(2):161-6. PubMed ID: 2758055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
    Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
    Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of H2-receptor antagonists on platelet function in vitro.
    Nakamura K; Kariyazono H; Shinkawa T; Yamaguchi T; Yamashita T; Ayukawa O; Moriyama Y; Yotsumoto G; Toyohira H; Taira A; Yamada K
    Hum Exp Toxicol; 1999 Aug; 18(8):487-92. PubMed ID: 10462360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of novel platelet aggregation inhibitors on human blood platelet clustering and retention effected by some polymer materials, in vitro.
    Lasslo A; Quintana RP; Crisan D; Baier RE; Meyer AE; Fornalik MS
    Med Prog Technol; 1983-1984; 10(2):71-88. PubMed ID: 6674737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of novel aggregation inhibitors on serotonin uptake by human blood platelets.
    Lasslo A; Dillingham EO; Gollamudi R; Carter-Burks G
    Biochim Biophys Acta; 1987 Mar; 923(3):443-50. PubMed ID: 3828386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dependence of the antagonism at human platelet 5-HT2 receptors by ketanserin on the reaction pH.
    De Clerck F; Xhonneux B; Tollenaere JP; Janssen PA
    Thromb Res; 1985 Dec; 40(5):581-96. PubMed ID: 2935970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between chemical structure and inhibition of ADP-stimulated human thrombocyte release of serotonin and platelet factor 4.
    Dillingham EO; Lasslo A; Carter-Burks G; Bond SE; Gollamudi R
    Biochim Biophys Acta; 1989 Feb; 990(2):128-32. PubMed ID: 2917173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (2-Piperidine)- and (2-pyrrolidine)ethanones and -ethanols as inhibitors of blood platelet aggregation.
    Grisar JM; Claxton GP; Stewart KT; MacKenzie RD; Kariya T
    J Med Chem; 1976 Oct; 19(10):1195-201. PubMed ID: 994149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and structure-activity relationships of potent GPIIb/IIIa antagonists: discovery of FK419.
    Yamanaka T; Ohkubo M; Kuroda S; Nakamura H; Takahashi F; Aoki T; Mihara K; Seki J; Kato M
    Bioorg Med Chem; 2005 Jul; 13(13):4343-52. PubMed ID: 15927840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains.
    Meanwell NA; Pearce BC; Roth HR; Smith EC; Wedding DL; Wright JJ; Buchanan JO; Baryla UM; Gamberdella M; Gillespie E
    J Med Chem; 1992 Jul; 35(14):2672-87. PubMed ID: 1321910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Part II: piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
    Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Harris PK; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1388-94. PubMed ID: 20097563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of piperidine-3-carboxamides as human platelet aggregation inhibitors.
    Zheng X; Salgia SR; Thompson WB; Dillingham EO; Bond SE; Feng Z; Prasad KR; Gollamudi R
    J Med Chem; 1995 Jan; 38(1):180-8. PubMed ID: 7837229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorinated benzyloxyphenyl piperidine-4-carboxamides with dual function against thrombosis: inhibitors of factor Xa and platelet aggregation.
    de Candia M; Liantonio F; Carotti A; De Cristofaro R; Altomare C
    J Med Chem; 2009 Feb; 52(4):1018-28. PubMed ID: 19193009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Alkynyl derivatives of adenosine-5'-N-ethyluronamide: selective A2 adenosine receptor agonists with potent inhibitory activity on platelet aggregation.
    Cristalli G; Volpini R; Vittori S; Camaioni E; Monopoli A; Conti A; Dionisotti S; Zocchi C; Ongini E
    J Med Chem; 1994 May; 37(11):1720-6. PubMed ID: 8201607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of lidocaine, codeine and vadocaine hydrochloride on platelet aggregation in human platelet-rich plasma.
    Kangasaho M
    Arzneimittelforschung; 1988 Apr; 38(4A):613-6. PubMed ID: 2840087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of MDL 28,133A, a 5-HT2 receptor antagonist, on platelet aggregation and coronary thrombosis in dogs.
    Hsieh CP; Sakai K; Bruns GC; Dage RC
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):761-72. PubMed ID: 7532754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of latamoxef (moxalactam) and its related compounds on platelet aggregation in vitro--structure activity relationships.
    Uchida K; Kakushi H; Shike T
    Thromb Res; 1987 Jul; 47(2):215-22. PubMed ID: 3477883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.